Searched for
LUNESTA
India a stock pickers' market; top ten stocks to bet on for next 12 monthsIndia has always been a stock pickers' market. Here is a list of 10 stocks from different brokerage firms for 6-12 months.- Sharekhan picks top investment ideas as market fall makes valuations reasonableThe stocks may remain subdued for another quarter or two due to a slow recovery in earnings and this time should be utilized to build a por...
- Sharekhan’s top 12 picks which may give up to 50% return in next 6-12 monthsEquity market has underperformed other EMs in the last few months due to rising concerns over subdued growth in the earnings segment.
- Sharekhan's top 12 stocks which can give up to 26% return in next 6-12 monthsRise on daily chart was a three-wave advance which further indicates that the bounce was corrective in nature. In other words, it was just ...
- Dr Reddy's launches insomnia drug in US; Glenmark gets FDA nodThe company has started selling 1 mg, 2 mg and 3 mg tablets of Eszopiclone, a generic version of Lunesta, a sedative drug that is used for ...
- Sharekhan’s top 11 stock picks that can return upto 26% in FebruarySensex plunged over 800 points last week as dovish guidance from the RBI and further tapering by the US Federal Reserve weighed on investor...
- Dr Reddy's Laboratories will infringe on Lunesta's patent: US court of appealThe United States Court of Appeals for the Federal Circuit has ruled that Dr Reddy's Laboratories Ltd will (rpt will) infringe on the paten...
- Sensex reverses gains: Top eleven stocks in focusThe BSE Sensex quickly reversed gains in mid-morning trade and slipped in red. Take a look at top eleven stocks in focus.
- Dr Reddy's under pressure on losing appeal for LunestaDr Reddy's Laboratories were witnessing profit booking on reports that the company has lost a patent case for generic version of Lunesta.
- Eleven stocks in focus in Friday morning tradeIndian markets are likely to trade in a range. Here is a list of eleven stocks which are likely to be in focus in trade today.
- Credit Suisse downgrades Lupin, cites unfavourable risk rewardCredit Suisse has downgraded Lupin from ‘outperform’ to ‘neutral’ rating as risk reward appears unfavourable, Asia Pacific-focused broker s...
- Lupin settles litigation over Lunesta with Japanese firmDrug firm Lupin on Monday said it has settled ongoing litigation over Lunesta tablets, used in treating insomnia, with Japan-based Dainippo...
- Lupin settles litigation over Lunesta tablets; stock upPharma major Lupin and its subsidiary Lupin Pharmaceuticals Inc have settled ongoing litigation with Sunovion Pharmaceuticals over Lunesta ...
- FDA nod for three Glenmark drugsGlenmark Pharmaceuticals said it has received the US health regulator's approval to market three generic products in the American market.
Load More
